妇科恶性肿瘤前哨淋巴结活检的争议
本文为范围综述,识别了子宫内膜癌和宫颈癌前哨淋巴结(SLN)活检的关键争议。检索PubMed、Cochrane图书馆和NCCN指南,纳入高质量研究。证据支持SLN活检在高级别子宫内膜癌和宫颈癌分期中的准确性,对浸润性子宫内膜癌具有成本效益;但肿瘤学结局、患者发病率影响及孤立肿瘤细胞是否辅助治疗尚缺乏结论性证据。
要点
- SLN活检对高分级子宫内膜癌和宫颈癌分期准确性有充分证据支持。
- SLN活检对浸润性子宫内膜癌似乎是具有成本效益的策略。
- 肿瘤学结局、发病率影响及孤立肿瘤细胞处理仍存争议,需进一步试验。
核心结论
- SLN活检是宫颈癌和子宫内膜癌手术公认的分期策略,但如何最安全有效地应用仍存争议,需进一步临床试验和更大样本观察解决。
研究设计与样本
- 范围综述,检索PubMed、Cochrane图书馆高级检索和NCCN指南,纳入大样本、I级证据或前瞻性试验,缺乏时纳入高质量期刊的关键观察性系列。
主要发现
- 充分证据支持SLN活检在高分级子宫内膜癌和宫颈癌分期中的准确性。
- SLN活检似乎对浸润性子宫内膜癌是具有成本效益的策略。
- 关于SLN活检的肿瘤学结局、对患者发病率的影响以及临床医生是否应辅助治疗SLN中孤立肿瘤细胞,缺乏结论性证据。
关键数值与推荐
- 检索词包括SLN活检对高分级子宫内膜癌或>2-cm宫颈癌的准确性、妇科癌症成本效益、低体积转移临床意义、发病率及癌症生存影响。
- 研究选择标准为大样本、I级证据或前瞻性试验;缺乏时纳入高质量期刊的关键观察性系列。
临床怎么用
- SLN活检可用于宫颈癌和子宫内膜癌分期,尤其高分级子宫内膜癌和宫颈癌准确性有证据支持。
- 对浸润性子宫内膜癌可考虑SLN活检作为成本效益策略。
- 孤立肿瘤细胞的辅助治疗决策需个体化,因证据不足。
局限性
- 关于肿瘤学结局、发病率影响和孤立肿瘤细胞处理的证据缺乏结论性。
- 需进一步临床试验和更大样本观察解决争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sentinel lymph node (SLN) biopsy represents an evolution in the advancement of minimally invasive surgical techniques for gynecologic cancers. Prospective and retrospective studies have consistently shown its accuracy in the detection of lymph node metastases for endometrial and cervical cancers. However, consistent with any emerging surgical technique in the early phases of adoption, new questions have arisen regarding its application and impact. This paper served as a scoping review to identify the key controversies that have arisen in the field of SLN biopsy for endometrial and cervical cancers. DATA SOURCES: Several key controversies were identified, and PubMed, the Cochrane Library (cochranelibrary.com) advanced search function, and the National Comprehensive Cancer Network guidelines were searched for supporting evidence. These included search terms such as "the accuracy of SLN biopsy for high grade endometrial cancer or cervical cancers >2-cm," "cost effectiveness of SLN biopsy for gynecologic cancers," "clinical significance of low volume metastases in endometrial cancer," "morbidity of SLN biopsy for endometrial and cervical cancer," and "impact on cancer survival of SLN biopsy for endometrial and cervical cancer." METHODS OF STUDY SELECTION: Studies were selected for review if they included significant numbers of patients, were level I evidence, or were prospective trials. Where this level of evidence failed to exist, seminal observational series that were published in high-quality journals were included. TABULATION, INTEGRATION, AND RESULTS: Similar studies were listed and subcategorized and cross-compared, excluding those that included repeated analyses of the same patient populations. The relevant clinical trials or observational studies were clustered and reviewed for each chosen controversy. Adequate evidence supports the accuracy of SLN biopsy in the staging of high-grade endometrial cancer and cervical cancer, and it seems to be a cost-effective strategy for invasive endometrial cancer. Conclusive evidence was lacking with respect to the oncologic outcomes related to SLN biopsy, the impact on patient morbidity, and whether clinicians should treat isolated tumor cells in SLNs with adjuvant therapy. CONCLUSION: SLN biopsy is an accepted staging strategy for cervical and endometrial cancer surgery; however, controversies remain in how it can be applied with the most safety and efficacy. These ultimately need to be resolved with further clinical trials and observations of larger series of patients.
引用
- Rossi EC, Tanner E. Controversies in Sentinel Lymph Node Biopsy for Gynecologic Malignancies. J Minim Invasive Gynecol. 2020. PMID: 33359741. doi:10.1016/j.jmig.2020.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。